Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Congenital hypothyroidism due to transplacental passage of maternal thyroid-stimulating hormone (TSH)-binding inhibitory antibodies is a type of transient congenital hypothyroidism, a thyroid hormone deficiency that is not permanent.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
No clinical trials have been registered for congenital hypothyroidism due to transplacental passage of maternal TSH-binding inhibitory antibodies.
1 publication has been identified in PubMed for congenital hypothyroidism due to transplacental passage of maternal TSH-binding inhibitory antibodies. Research spans Review / Meta-Analysis (100%).
Tzoraki M (2024). [PMID: 39749069](https://pubmed.ncbi.nlm.nih.gov/39749069/). *Cureus*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 8:35 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center